Interest of crizotinib in a lung cancer patient with de novo amplification of MET

被引：0

作者：

Rabeau, A. ^{[1
]}

Rouquette, I. ^{[2
]}

Vantelon, J. -M. ^{[3
]}

Taranchon-Clermont, E. ^{[2
]}

Mazieres, J. ^{[1
]}

机构：

[1] Univ Paul Sabatier, CHU Toulouse, Hop Larrey, Serv Pneumol, F-31400 Toulouse, France

[2] CHU Toulouse, IUCT Oncopole, Serv Pathol, F-31100 Toulouse, France

[3] Clin Occitanie, F-31600 Muret, France

来源：

REVUE DES MALADIES RESPIRATOIRES | 2017年 / 34卷 / 01期

关键词：

Lung adenocarcinoma; MET; Crizotinib; Targeted therapy; PLUS ERLOTINIB; NSCLC;

D O I：

10.1016/j.rmr.2016.05.007

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Targeted therapy in lung cancer changes the prognostic and treatment of patients. MET is an oncogene including exon 14 mutations and gene amplification associated with worse prognosis. We here report the case of a 47-year-old former smoker, woman, with a stage IV lung adenocarcinoma with multiple chemotherapy failure. A MET amplification was identified and the patient consequently received crizotinib. A major response was observed after eight weeks of treatment. MET amplification screening appears to be interesting with some oncogenic-addicted tumor response rate. Those patients should be enrolled in clinical trials dedicated to tumor with MET alteration. (C) 2016 SPLF. Published by Elsevier Masson SAS. All rights reserved.

引用

页码：57 / 60

页数：4

共 10 条

[1]

[Anonymous], ACTIVITY CRIZOTINIB

[2] Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) [J].

Camidge, D. Ross ;

Ou, Sai-Hong Ignatius ;

Shapiro, Geoffrey ;

Otterson, Gregory Alan ;

Villaruz, Liza Cosca ;

Villalona-Calero, Miguel Angel ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Dacic, Sanja ;

Cardarella, Stephanie ;

Zhao, Weiqiang ;

Tye, Lesley ;

Stephenson, Patricia ;

Wilner, Keith D. ;

James, Leonard Philip ;

Socinski, Mark A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[3] Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases [J].

Costa, Daniel B. ;

Shaw, Alice T. ;

Ou, Sai-Hong I. ;

Solomon, Benjamin J. ;

Riely, Gregory J. ;

Ahn, Myung-Ju ;

Zhou, Caicun ;

Shreeve, S. Martin ;

Selaru, Paulina ;

Polli, Anna ;

Schnell, Patrick ;

Wilner, Keith D. ;

Wiltshire, Robin ;

Camidge, D. Ross ;

Crino, Lucio .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1881-1888

[4] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

[5]

Garajova Ingrid, 2015, Transl Oncogenomics, V7, P13, DOI 10.4137/TOG.S30534

[6] Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations [J].

Liu, Xuewen ;

Jia, Yuxia ;

Stoopler, Mark B. ;

Shen, Yufeng ;

Cheng, Haiying ;

Chen, Jinli ;

Mansukhani, Mahesh ;

Koul, Sanjay ;

Halmos, Balazs ;

Borczuk, Alain C. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) :794-+

[7] Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer [J].

Okuda, Katsuhiro ;

Sasaki, Hidefumi ;

Yukiue, Haruhiro ;

Yano, Motoki ;

Fujii, Yoshitaka .

CANCER SCIENCE, 2008, 99 (11) :2280-2285

[8] Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification [J].

Ou, Sai-Hong Ignatius ;

Kwak, Eunice L. ;

Siwak-Tapp, Christina ;

Dy, Joni ;

Bergethon, Kristin ;

Clark, Jeffrey W. ;

Camidge, D. Ross ;

Solomon, Benjamin J. ;

Maki, Robert G. ;

Bang, Yung-Jue ;

Kim, Dong-Wan ;

Christensen, James ;

Tan, Weiwei ;

Wilner, Keith D. ;

Salgia, Ravi ;

Iafrate, A. John .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (05) :942-946

[9] Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer [J].

Scagliotti, Giorgio ;

von Pawel, Joachim ;

Novello, Silvia ;

Ramlau, Rodryg ;

Favaretto, Adolfo ;

Barlesi, Fabrice ;

Akerley, Wallace ;

Orlov, Sergey ;

Santoro, Armando ;

Spigel, David ;

Hirsh, Vera ;

Shepherd, Frances A. ;

Sequist, Lecia V. ;

Sandler, Alan ;

Ross, Jeffrey S. ;

Wang, Qiang ;

von Roemeling, Reinhard ;

Shuster, Dale ;

Schwartz, Brian .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) :2667-+

[10]

Spigel DR, 2014, J CLIN ONCOL, V32

← 1 →